ADVERTISEMENT
Millennium Health, University of Cincinnati to Study Precipitated Withdrawal During Buprenorphine Induction
Millennium Health, a specialty lab focused on medication monitoring and drug testing, has announced a collaboration with the University of Cincinnati to study precipitated withdrawal during buprenorphine induction.
Precipitated withdrawal involves abdominal cramps, vomiting, intense pain, and anxiety, creating potential barriers to opioid use disorder treatment. Funded by a grant from the National Institute on Drug Abuse (NIDA), the research will look to uncover more information about the extent, regional variation, and frequency of precipitated withdrawal during buprenorphine induction, as well as identify factors that can increase its likelihood.
Findings could help clinicians identify patient risk factors for precipitated withdrawal and inform future treatment approaches.
“We are eager to learn from the experiences and insight of clinicians prescribing buprenorphine who face these challenges daily,” Eric Dawson, PharmD, vice president, clinical affairs, Millennium Health, and study co-investigator, said in a news release. “By matching urine drug test results at the county level with the aggregated clinician survey data, we hope to learn more about predictors of buprenorphine-induced precipitated withdrawal, especially as it pertains to fentanyl use.”
Reference
